Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Biol Macromol ; 254(Pt 1): 127596, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37898250

ABSTRACT

Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is an aggressive B-ALL malignancy associated with high rates of relapse and inferior survival rate. While targeted treatments against the cell surface proteins CD22 or CD19 have been transformative in the treatment of refractory B-ALL, patients may relapse due to antigen loss, necessitating targeting alternative antigens. Cytokine receptor-like factor 2 (CRLF2) is overexpressed in half of Ph-like ALL cases conferring chemoresistance and enhancement of leukemia cell survival. Therefore, targeting CRLF2 may reduce the likelihood of relapse associated with antigen loss. We developed a CRLF2-targeting single-chain variable fragment modified by the fragment crystallizable region (CRLF2 scFv-Fc) conjugated to a drug maytansinoid 1 (DM1)-DOPC liposomal conjugate, creating homogeneous CRLF2-targeted liposomes (CRLF2-DM1 LIP). Cellular association and internalization studies in a Ph-like ALL cell line, MHH-CALL-4, compared to its lentivirally transduced CRLF2-knockdown counterpart (KD-CALL-4) revealed excellent CRLF2-targeting efficiency of CRLF2-DM1 LIP. Moreover, CRLF2-DM1 LIP showed selective association and internalization ex vivo using Ph-like ALL patient-derived xenograft (PDX) cells with minimal reactivity with non-target cells. Cell apoptosis assays demonstrated the CRLF2-dependent potency of CRLF2-DM1 LIP in Ph-like ALL cell lines. This study is the first to highlight the therapeutic potential of a CRLF2-directed scFv-Fc-liposomal conjugate for targeting Ph-like ALL.


Subject(s)
Immunoconjugates , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Animals , Humans , Immunoglobulin Fragments , Liposomes/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Disease Models, Animal , Immunoconjugates/pharmacology , Recurrence
2.
Int J Biol Macromol ; 190: 214-223, 2021 Nov 01.
Article in English | MEDLINE | ID: mdl-34481852

ABSTRACT

Antibody fragments are promising building blocks for developing targeted therapeutics, thus improving treatment efficacy while minimising off-target toxicity. Despite recent advances in targeted therapeutics, patients with Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL), a high-risk malignancy, lack specific and effective targeted treatments. Cytokine receptor-like factor 2 (CRLF2) is overexpressed in 50% of Ph-like ALL cases, conferring the survival of leukemia blasts through activation of the JAK/STAT signalling pathway. Targeting such a vital cell-surface protein could result in potent anti-leukaemic efficacy and reduce the likelihood of relapse associated with antigen loss. Herein, we developed a novel single-chain variable fragment (scFv) against CRLF2 based on a monoclonal antibody raised against the recombinant extracellular domain of human TSLPRα chain. The scFv fragment demonstrated excellent binding affinity with CRLF2 protein in the nanomolar range. Cellular association studies in vitro using an inducible CRLF2 knockdown cell line and ex vivo using patient-derived xenografts revealed the selective association of the scFv with CRLF2. The fragment exhibited significant receptor antagonistic effects on STAT5 signalling, suggesting possible therapeutic implications in vivo. This study is the first to describe the potential use of a novel scFv for targeting Ph-like ALL.


Subject(s)
Immunoglobulin Fragments/metabolism , Philadelphia Chromosome , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Receptors, Cytokine/metabolism , Recombinant Proteins/metabolism , Animals , Cell Line, Tumor , Child , Endocytosis , HEK293 Cells , Humans , Mice , Phosphorylation , STAT5 Transcription Factor/metabolism , Signal Transduction , Single-Chain Antibodies/isolation & purification
3.
Pathol Res Pract ; 206(11): 768-71, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20850227

ABSTRACT

AIMS: The study intended to reveal whether HPV infection is reflected by nuclear morphology and DNA cytometry parameters in head and neck squamous cell carcinomas (HNSCC). METHODS: In total, 39 HNSCC were selected for reanalysis by histomorphology applying the core classification, DNA cytometry and HPV detection. For the core classification, HE sections were assessed by a score system to evaluate the nuclear size, the mitosis size, their variabilities and the presence of tripolar or tetrapolar mitoses. HPV was analyzed by consensus PCR followed by a hybridization method for virus typing. Static DNA cytometry was applied on single cell suspension focusing particularly on the parameters DNA modal value, DNA index peak, DNA index mean, 2c deviation index and 5c exceeding rate. Statistical analysis was done by T-test or Fisher's exact test. RESULTS: The analysis revealed that HPV positive HNSCC had significantly smaller nuclei than HPV negative cases. Increasing values of the nuclear size and mitosis size were significantly associated with higher indices of the DNA cytometry analysis. CONCLUSIONS: The study confirms that the core classification can provide information on the ploidy of HNSCC and that HPV positive tumors represent a distinct morphological and genetic carcinoma subtype.


Subject(s)
Carcinoma, Squamous Cell/classification , DNA, Neoplasm/genetics , Head and Neck Neoplasms/classification , Papillomaviridae/isolation & purification , Papillomavirus Infections/classification , Ploidies , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/virology , Cell Nucleus/pathology , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/virology , Humans , Image Cytometry/methods , Mitosis , Papillomaviridae/genetics , Papillomavirus Infections/genetics , Papillomavirus Infections/virology
4.
Lung Cancer ; 65(3): 312-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19168259

ABSTRACT

We attempted to establish a microscopy based tumour characterization providing insight into the genetics of cancer cells and in particular their DNA ploidy. The core classification defined semi-quantitative criteria for scoring the nuclear size ranging from small (core score 1) to giant nuclei (core score 4). By listing all nuclear sizes according to their relative frequencies it provided a measure for core size variability as a correlate of nuclear pleomorphism. Additionally, the mitosis size, their variability and the presence/abundance of tripolar and tetrapolar mitoses were determined. This classification was applied to 155 lung cancer samples from all major histologic types and the results were correlated with the analysis by DNA image cytometry and patient survival. The morphological assessments correlated highly significantly with the DNA ploidy parameters, e.g. small cell lung carcinomas showed the smallest values for nuclear size (mean core score of 1.18) and DNA content (DNA index mean of 2.08c) being highly significantly different from adenocarcinomas (1.95/3.10c), large cell lung carcinoma (2.00/3.26c) and squamous cell carcinoma (2.20/3.42c). In non-small cell lung carcinoma (NSCLC) in general and adenocarcinoma in particular, the core size variability correlated significantly with grading and survival. Furthermore, parameters indicative for chromosomal variability, i.e. 2c deviation index and 5c exceeding rate, were predictors of poor survival in NSCLC patients. As a complement to histologic tumour diagnosis the core classification should help to better stratify cancer subtypes.


Subject(s)
Cell Nucleus/ultrastructure , DNA, Neoplasm/analysis , Lung Neoplasms/classification , Lung Neoplasms/genetics , Cell Nucleus/genetics , Chromosome Aberrations , Disease Progression , Female , Humans , Image Cytometry , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Lung Neoplasms/physiopathology , Lung Neoplasms/ultrastructure , Male , Mitosis , Organelle Size , Ploidies , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL